Cargando…

Prognostic utility of systemic inflammatory markers and chronic hepatitis C virus infection status in hepatocellular carcinoma patients treated with local ablation

BACKGROUND: Hepatocellular carcinoma (HCC) has high incidence and mortality worldwide. Local ablation using radiofrequency ablation (RFA) or microwave ablation (MWA) is potentially curative for early-stage HCC with outcomes comparable to surgical resection. We explored the influence of demographic,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Mohamed Abdulwahab Mohamed, Harmsen, William Scott, Morsy, Khairy Hammam, Galal, Ghada Moustapha Kamal, Therneau, Terry M., Roberts, Lewis Rowland
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8887142/
https://www.ncbi.nlm.nih.gov/pubmed/35227234
http://dx.doi.org/10.1186/s12885-021-09121-8
_version_ 1784660836737875968
author Ali, Mohamed Abdulwahab Mohamed
Harmsen, William Scott
Morsy, Khairy Hammam
Galal, Ghada Moustapha Kamal
Therneau, Terry M.
Roberts, Lewis Rowland
author_facet Ali, Mohamed Abdulwahab Mohamed
Harmsen, William Scott
Morsy, Khairy Hammam
Galal, Ghada Moustapha Kamal
Therneau, Terry M.
Roberts, Lewis Rowland
author_sort Ali, Mohamed Abdulwahab Mohamed
collection PubMed
description BACKGROUND: Hepatocellular carcinoma (HCC) has high incidence and mortality worldwide. Local ablation using radiofrequency ablation (RFA) or microwave ablation (MWA) is potentially curative for early-stage HCC with outcomes comparable to surgical resection. We explored the influence of demographic, clinical, and laboratory factors on outcomes of HCC patients receiving ablation. METHODS: This retrospective cohort study included 221 HCC patients receiving local ablation at Mayo Clinic between January 2000 and October 2018, comprising 140 RFA and 81 MWA. Prognostic factors determining overall survival (OS) and disease-free survival (DFS) were identified using multivariate analysis. RESULTS: There was no clinically significant difference in OS or DFS between RFA and MWA. In multivariate analysis of OS, pre-ablation lymphocyte-monocyte ratio [Hazard ratio (HR) 0.7, 95% confidence interval (CI) 0.58–0.84, P = 0.0001], MELD score [HR 1.12, 95%CI 1.068–1.17, P <  0.0001], tumor number [HR 1.23, 95%CI 1.041–1.46, P = 0.015] and tumor size [HR 1.18, 95%CI 1.015–1.37, P = 0.031] were clinically-significant prognostic factors. Among HCC patients with chronic hepatitis C (HCV) infection, positive HCV PCR at HCC diagnosis was associated with 1.4-fold higher hazard of death, with 5-year survival of 32.8% vs 53.6% in HCV PCR-negative patients. Regarding DFS, pre-ablation lymphocyte-monocyte ratio [HR 0.77, 95%CI 0.66–0.9, P = 0.001], MELD score [HR 1.06, 95%CI 1.022–1.11, P = 0.002], Log(2) AFP [HR 1.11, 95%CI 1.033–1.2, P = 0.005], tumor number [HR 1.29, 95%CI 1.078–1.53, P = 0.005] and tumor size [HR 1.25, 95%CI 1.043–1.51 P = 0.016] were independently prognostic. CONCLUSIONS: Pre-ablation systemic inflammation represented by lymphocyte-monocyte ratio is significantly associated with OS and DFS in HCC patients treated with local ablation. HCV viremia is associated with poor OS. Tumor biology represented by tumor number and size are strongly prognostic for OS and DFS while AFP is significantly associated with DFS only.
format Online
Article
Text
id pubmed-8887142
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88871422022-03-17 Prognostic utility of systemic inflammatory markers and chronic hepatitis C virus infection status in hepatocellular carcinoma patients treated with local ablation Ali, Mohamed Abdulwahab Mohamed Harmsen, William Scott Morsy, Khairy Hammam Galal, Ghada Moustapha Kamal Therneau, Terry M. Roberts, Lewis Rowland BMC Cancer Research BACKGROUND: Hepatocellular carcinoma (HCC) has high incidence and mortality worldwide. Local ablation using radiofrequency ablation (RFA) or microwave ablation (MWA) is potentially curative for early-stage HCC with outcomes comparable to surgical resection. We explored the influence of demographic, clinical, and laboratory factors on outcomes of HCC patients receiving ablation. METHODS: This retrospective cohort study included 221 HCC patients receiving local ablation at Mayo Clinic between January 2000 and October 2018, comprising 140 RFA and 81 MWA. Prognostic factors determining overall survival (OS) and disease-free survival (DFS) were identified using multivariate analysis. RESULTS: There was no clinically significant difference in OS or DFS between RFA and MWA. In multivariate analysis of OS, pre-ablation lymphocyte-monocyte ratio [Hazard ratio (HR) 0.7, 95% confidence interval (CI) 0.58–0.84, P = 0.0001], MELD score [HR 1.12, 95%CI 1.068–1.17, P <  0.0001], tumor number [HR 1.23, 95%CI 1.041–1.46, P = 0.015] and tumor size [HR 1.18, 95%CI 1.015–1.37, P = 0.031] were clinically-significant prognostic factors. Among HCC patients with chronic hepatitis C (HCV) infection, positive HCV PCR at HCC diagnosis was associated with 1.4-fold higher hazard of death, with 5-year survival of 32.8% vs 53.6% in HCV PCR-negative patients. Regarding DFS, pre-ablation lymphocyte-monocyte ratio [HR 0.77, 95%CI 0.66–0.9, P = 0.001], MELD score [HR 1.06, 95%CI 1.022–1.11, P = 0.002], Log(2) AFP [HR 1.11, 95%CI 1.033–1.2, P = 0.005], tumor number [HR 1.29, 95%CI 1.078–1.53, P = 0.005] and tumor size [HR 1.25, 95%CI 1.043–1.51 P = 0.016] were independently prognostic. CONCLUSIONS: Pre-ablation systemic inflammation represented by lymphocyte-monocyte ratio is significantly associated with OS and DFS in HCC patients treated with local ablation. HCV viremia is associated with poor OS. Tumor biology represented by tumor number and size are strongly prognostic for OS and DFS while AFP is significantly associated with DFS only. BioMed Central 2022-02-28 /pmc/articles/PMC8887142/ /pubmed/35227234 http://dx.doi.org/10.1186/s12885-021-09121-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ali, Mohamed Abdulwahab Mohamed
Harmsen, William Scott
Morsy, Khairy Hammam
Galal, Ghada Moustapha Kamal
Therneau, Terry M.
Roberts, Lewis Rowland
Prognostic utility of systemic inflammatory markers and chronic hepatitis C virus infection status in hepatocellular carcinoma patients treated with local ablation
title Prognostic utility of systemic inflammatory markers and chronic hepatitis C virus infection status in hepatocellular carcinoma patients treated with local ablation
title_full Prognostic utility of systemic inflammatory markers and chronic hepatitis C virus infection status in hepatocellular carcinoma patients treated with local ablation
title_fullStr Prognostic utility of systemic inflammatory markers and chronic hepatitis C virus infection status in hepatocellular carcinoma patients treated with local ablation
title_full_unstemmed Prognostic utility of systemic inflammatory markers and chronic hepatitis C virus infection status in hepatocellular carcinoma patients treated with local ablation
title_short Prognostic utility of systemic inflammatory markers and chronic hepatitis C virus infection status in hepatocellular carcinoma patients treated with local ablation
title_sort prognostic utility of systemic inflammatory markers and chronic hepatitis c virus infection status in hepatocellular carcinoma patients treated with local ablation
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8887142/
https://www.ncbi.nlm.nih.gov/pubmed/35227234
http://dx.doi.org/10.1186/s12885-021-09121-8
work_keys_str_mv AT alimohamedabdulwahabmohamed prognosticutilityofsystemicinflammatorymarkersandchronichepatitiscvirusinfectionstatusinhepatocellularcarcinomapatientstreatedwithlocalablation
AT harmsenwilliamscott prognosticutilityofsystemicinflammatorymarkersandchronichepatitiscvirusinfectionstatusinhepatocellularcarcinomapatientstreatedwithlocalablation
AT morsykhairyhammam prognosticutilityofsystemicinflammatorymarkersandchronichepatitiscvirusinfectionstatusinhepatocellularcarcinomapatientstreatedwithlocalablation
AT galalghadamoustaphakamal prognosticutilityofsystemicinflammatorymarkersandchronichepatitiscvirusinfectionstatusinhepatocellularcarcinomapatientstreatedwithlocalablation
AT therneauterrym prognosticutilityofsystemicinflammatorymarkersandchronichepatitiscvirusinfectionstatusinhepatocellularcarcinomapatientstreatedwithlocalablation
AT robertslewisrowland prognosticutilityofsystemicinflammatorymarkersandchronichepatitiscvirusinfectionstatusinhepatocellularcarcinomapatientstreatedwithlocalablation